BrightPath Biotherapeutics Co (TSE:4594) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 11, 2026)


TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
46 GF Score
Price 円50.00
GF Value 円4.64
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

BrightPath Biotherapeutics Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

TSE:4594 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BrightPath Biotherapeutics Co Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Margin of Safety % (DCF Dividends Based) falls into.


TSE:4594
46GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?

Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued. The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64. GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.

Key valuation signals for TSE:4594:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score

Get the complete analysis for TSE:4594

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円50.00
Price
円4.64
GF Value